SERB Pharmaceuticals is a fast-growing global specialty pharma company designed to address rare and urgent conditions by delivering life-saving medicines when time and complexity leave no room for failure.
Completion of the transaction is subject to customary conditions, including required foreign direct investment (FDI) regulatory approval, which is expected to be completed within 60 days.
Mayer Brown advises SERB Pharmaceuticals on the structuring of the transaction with a team led by Tax partner Olivier Parawan, and included counsel Jean-Philippe Coiffard, and Dominique Ehinger.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
